Celltrion Signs Exclusive Supply Deals for Omlyclo and Aptozma in the US
Predicted impact: Medium
US exclusive supply deals for two biosimilars; contract size not disclosed, likely meaningful for revenue.
Celltrion셀트리온
068270 · KOSPI · ₩CELLTRION · 셀트리온
₩190,000▼ ₩4,400 (2.26%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y +6.50%
TP5 ₩245,000TP4 ₩227,500TP3 ₩218,500TP2 ₩210,000TP1 ₩204,000Entry ₩198,200DCA1 ₩195,300DCA2 ₩192,400DCA3 ₩189,500STOP ₩186,600
Entry, trailing stop, targets and DCA levels of the current Squeeze! setup (paper-trading levels from a fixed rule, not advice).
- Market cap
- ₩44T
- Enterprise value
- ₩47T
- P/E
- 28.0×
- P/B
- 2.5×
- Dividend yield
- 0.0%
- ROE
- 8.8%
- Net margin
- 32.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−24.3% from the high
₩158,500Today: ₩188,000 – ₩196,900₩251,000
Returns
- 1W−4.1%
- 1M+7.1%
- 3M+6.3%
- 6M−6.9%
- YTD+5.0%
- 1Y+9.9%
- Volume today
- 431,926
- 0.9× the 20-day average
- Traded today
- ₩82B
- Listed shares
- 232,072,877
- EPS (12 months)
- ₩6,791
- Earnings yield 3.6%
AI research · Update noteCelltrion Q3 2026 Preliminary Results: Revenue ₩1.5T, Operating Income ₩510.0BThe preliminary Q3 results strengthen the evidence of an earnings recovery, with higher revenue and a margin of about 34.0%.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 57: in the news, paper buys.
- SentimentPositiveNews: Headlines focus on record quarterly results and new US supply deals. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat4.7% over the last month; the price is above its 20-day average.
- News impactHigh77 news items and filings in two weeks; 1 rated high impact, 22 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 26: sell ₩3.1B at the close (3.3% of 20-day average trading value)
On its 5 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 7.9% of trading value and pointed the same way 3 of 5 times.
- -2× KODEX 200 Futures Inverse 2X −₩1.9B
- 2× KODEX Leverage −₩649M
- -1× KODEX Inverse −₩368M
- -2× TIGER 200 Futures Inverse 2X −₩65M
- 2× TIGER Leverage −₩53M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 32 funds.
- KODEX 2001.0%
- TIGER 2001.0%
- KODEX 200TR1.0%
- KODEX Leverage2×1.0%
- RISE 2001.0%
- KIWOOM 200TR1.0%
- ACE 2001.0%
- PLUS 2001.0%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 190,800
Basis +0.42% · implied rate +9.0%
Open interest 32,411 contracts
Options open interest: 2,343 calls, 2,727 puts (put/call 1.16)
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Celltrion stock overview
Celltrion (셀트리온, KRX: 068270) is listed on KOSPI, in the Biotech & Pharma sector. This Korean biotechnology company develops and commercializes biopharmaceuticals for autoimmune diseases, tumors and other conditions, centered on biosimilars such as Remsima (CT-P13), the world's first antibody biosimilar, for which it has obtained global product approvals for 11 biosimilars. Its shares closed at ₩190,000 on Oct 26, 2026, down 2.26% on the day, giving it a market value of ₩44T.
Key facts
- Market cap
- ₩44T
- Sector
- Biotech & Pharma
- Latest price change
- −2.26%
- As of
- Oct 26, 2026
- Main business
- This Korean biotechnology company develops and commercializes biopharmaceuticals for autoimmune diseases, tumors and other conditions, centered on biosimilars such as Remsima (CT-P13), the world's first antibody biosimilar, for which it has obtained global product approvals for 11 biosimilars.
Quick answers about Celltrion
- What does Celltrion do?
- This Korean biotechnology company develops and commercializes biopharmaceuticals for autoimmune diseases, tumors and other conditions, centered on biosimilars such as Remsima (CT-P13), the world's first antibody biosimilar, for which it has obtained global product approvals for 11 biosimilars. Its products are sold in many countries, including Europe and the United States, mainly through direct sales subsidiaries, and it operates production facilities in Korea and at Branchburg in the United States. The company also pursues next-generation antibody research, including antibody-drug conjugates and multispecific antibodies.
- What is the market cap of Celltrion?
- The market capitalisation of Celltrion was ₩44T at the close on Oct 26, 2026.
- Who are the largest shareholders of Celltrion?
- According to the latest official filings, the largest reported holders are Celltrion Holdings (33.19%, as of Oct 27, 2026); National Pension Service (7.28%, as of Aug 3, 2026); Seo Jeong-jin (4.20%, as of Jul 3, 2026).
- When is the next earnings report from Celltrion?
- Korean companies rarely announce results dates in advance. Based on when Celltrion filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Celltrion?
- Yes. The National Pension Service held 7.28% of Celltrion shares as of Aug 3, 2026.
Company profile
This Korean biotechnology company develops and commercializes biopharmaceuticals for autoimmune diseases, tumors and other conditions, centered on biosimilars such as Remsima (CT-P13), the world's first antibody biosimilar, for which it has obtained global product approvals for 11 biosimilars. Its products are sold in many countries, including Europe and the United States, mainly through direct sales subsidiaries, and it operates production facilities in Korea and at Branchburg in the United States. The company also pursues next-generation antibody research, including antibody-drug conjugates and multispecific antibodies.
Written by AI from the company's latest annual report.
- Korean name
- 셀트리온
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)BiosimilarsContract drug manufacturing (CDMO)PharmaceuticalsUS tariffs & exportsWeak won, strong exporters
- Business group
- Celltrion
- CEO
- 기우성, 서진석
- Founded
- Feb 1991
- Listed
- Feb 2018
- Listed shares
- 232,072,877
- Fiscal year ends
- Month 12
- Website
- www.celltrion.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
- SK Bioscience302440 · ₩2.5T₩32,000−3.47%
Recent news
Samsung Biologics, Celltrion Hit Record Q3 Results, Intensifying Revenue Race
Predicted impact: Medium
Record Q3 results for a large biotech peer; read-across news with no direct size for this company.
[BioS] Celltrion Q3 revenue ₩1.5755T, operating profit ₩525.3B
High impactPredicted impact: High
Record Q3 results, revenue up 53% year on year; already reported repeatedly, so lowered one level.
Recent filings
See all- Amended: Preliminary earnings (consolidated)Oct 27, 2026
- 5%+ holding reportOct 27, 2026
- Share buyback decisionOct 26, 2026
- Major management matter relevant to investorsOct 22, 2026
- Report on Treasury Stock Acquisition ResultsOct 20, 2026
Titles in Korean until English translations are added.
Also known as: Celltrion / 셀트리온 / 068270 / KRX:068270
Source: KRX statistical information